Bayesian Phase II Single-Arm Designs
Author:
Teramukai Satoshi
Publisher
Springer Singapore
Reference23 articles.
1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. doi:
10.1093/jnci/92.3.205
.
2. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10. doi:
10.1016/0197-2456(89)90015-9
.
3. Zohar S, Teramukai S, Zhou Y. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial. Contemp Clin Trials. 2008;29:608–16. doi:
10.1016/j.cct.2007.11.005
.
4. Tan SB, Machin D. Bayesian two-stage designs for phase II clinical trials. Stat Med. 2002;21:1991–2012. doi:
10.1002/sim.1176
.
5. Mayo MS, Gajewski BJ. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors. Control Clin Trials. 2004;25:157–67. doi:
10.1016/j.cct.2003.11.006
.